Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Neurodegenerative Diseases market report explains the definition, types, applications, major countries, and major players of the Neurodegenerative Diseases market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Boehringer Ingelheim
Chongqing Zein Pharmaceutical
Eisai
Novartis
Bayer Schering Pharma AG
Addex Pharmaceutical
Yangtze River Pharmaceutical Group
AstraZeneca
Yumanity Therapeutics
HLundbeck A/S
Jiangsu Hansoh Pharmaceutical
Biogen Idec
Merck Serono
Bial
Asubio Pharmaceutical
Amarin
Alector
UCB
Pfizer
Teva Pharmaceutical
By Type:
NMDA
SSRIs
Dopamine Inhibitors
By End-User:
Parkinson’s disease
Huntington disease
Amyotrophic Lateral Sclerosis
Alzheimer’s disease
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Neurodegenerative Diseases Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Neurodegenerative Diseases Outlook to 2028- Original Forecasts
-
2.2 Neurodegenerative Diseases Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Neurodegenerative Diseases Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Neurodegenerative Diseases Market- Recent Developments
-
6.1 Neurodegenerative Diseases Market News and Developments
-
6.2 Neurodegenerative Diseases Market Deals Landscape
7 Neurodegenerative Diseases Raw Materials and Cost Structure Analysis
-
7.1 Neurodegenerative Diseases Key Raw Materials
-
7.2 Neurodegenerative Diseases Price Trend of Key Raw Materials
-
7.3 Neurodegenerative Diseases Key Suppliers of Raw Materials
-
7.4 Neurodegenerative Diseases Market Concentration Rate of Raw Materials
-
7.5 Neurodegenerative Diseases Cost Structure Analysis
-
7.5.1 Neurodegenerative Diseases Raw Materials Analysis
-
7.5.2 Neurodegenerative Diseases Labor Cost Analysis
-
7.5.3 Neurodegenerative Diseases Manufacturing Expenses Analysis
8 Global Neurodegenerative Diseases Import and Export Analysis (Top 10 Countries)
-
8.1 Global Neurodegenerative Diseases Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Neurodegenerative Diseases Export by Region (Top 10 Countries) (2017-2028)
9 Global Neurodegenerative Diseases Market Outlook by Types and Applications to 2022
-
9.1 Global Neurodegenerative Diseases Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global NMDA Consumption and Growth Rate (2017-2022)
-
9.1.2 Global SSRIs Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Dopamine Inhibitors Consumption and Growth Rate (2017-2022)
-
9.2 Global Neurodegenerative Diseases Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Parkinson’s disease Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Huntington disease Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Amyotrophic Lateral Sclerosis Consumption and Growth Rate (2017-2022)
-
9.2.4 Global Alzheimer’s disease Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Neurodegenerative Diseases Market Analysis and Outlook till 2022
-
10.1 Global Neurodegenerative Diseases Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Neurodegenerative Diseases Consumption (2017-2022)
-
10.2.2 Canada Neurodegenerative Diseases Consumption (2017-2022)
-
10.2.3 Mexico Neurodegenerative Diseases Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Neurodegenerative Diseases Consumption (2017-2022)
-
10.3.2 UK Neurodegenerative Diseases Consumption (2017-2022)
-
10.3.3 Spain Neurodegenerative Diseases Consumption (2017-2022)
-
10.3.4 Belgium Neurodegenerative Diseases Consumption (2017-2022)
-
10.3.5 France Neurodegenerative Diseases Consumption (2017-2022)
-
10.3.6 Italy Neurodegenerative Diseases Consumption (2017-2022)
-
10.3.7 Denmark Neurodegenerative Diseases Consumption (2017-2022)
-
10.3.8 Finland Neurodegenerative Diseases Consumption (2017-2022)
-
10.3.9 Norway Neurodegenerative Diseases Consumption (2017-2022)
-
10.3.10 Sweden Neurodegenerative Diseases Consumption (2017-2022)
-
10.3.11 Poland Neurodegenerative Diseases Consumption (2017-2022)
-
10.3.12 Russia Neurodegenerative Diseases Consumption (2017-2022)
-
10.3.13 Turkey Neurodegenerative Diseases Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Neurodegenerative Diseases Consumption (2017-2022)
-
10.4.2 Japan Neurodegenerative Diseases Consumption (2017-2022)
-
10.4.3 India Neurodegenerative Diseases Consumption (2017-2022)
-
10.4.4 South Korea Neurodegenerative Diseases Consumption (2017-2022)
-
10.4.5 Pakistan Neurodegenerative Diseases Consumption (2017-2022)
-
10.4.6 Bangladesh Neurodegenerative Diseases Consumption (2017-2022)
-
10.4.7 Indonesia Neurodegenerative Diseases Consumption (2017-2022)
-
10.4.8 Thailand Neurodegenerative Diseases Consumption (2017-2022)
-
10.4.9 Singapore Neurodegenerative Diseases Consumption (2017-2022)
-
10.4.10 Malaysia Neurodegenerative Diseases Consumption (2017-2022)
-
10.4.11 Philippines Neurodegenerative Diseases Consumption (2017-2022)
-
10.4.12 Vietnam Neurodegenerative Diseases Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Neurodegenerative Diseases Consumption (2017-2022)
-
10.5.2 Colombia Neurodegenerative Diseases Consumption (2017-2022)
-
10.5.3 Chile Neurodegenerative Diseases Consumption (2017-2022)
-
10.5.4 Argentina Neurodegenerative Diseases Consumption (2017-2022)
-
10.5.5 Venezuela Neurodegenerative Diseases Consumption (2017-2022)
-
10.5.6 Peru Neurodegenerative Diseases Consumption (2017-2022)
-
10.5.7 Puerto Rico Neurodegenerative Diseases Consumption (2017-2022)
-
10.5.8 Ecuador Neurodegenerative Diseases Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Neurodegenerative Diseases Consumption (2017-2022)
-
10.6.2 Kuwait Neurodegenerative Diseases Consumption (2017-2022)
-
10.6.3 Oman Neurodegenerative Diseases Consumption (2017-2022)
-
10.6.4 Qatar Neurodegenerative Diseases Consumption (2017-2022)
-
10.6.5 Saudi Arabia Neurodegenerative Diseases Consumption (2017-2022)
-
10.6.6 United Arab Emirates Neurodegenerative Diseases Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Neurodegenerative Diseases Consumption (2017-2022)
-
10.7.2 South Africa Neurodegenerative Diseases Consumption (2017-2022)
-
10.7.3 Egypt Neurodegenerative Diseases Consumption (2017-2022)
-
10.7.4 Algeria Neurodegenerative Diseases Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Neurodegenerative Diseases Consumption (2017-2022)
-
10.8.2 New Zealand Neurodegenerative Diseases Consumption (2017-2022)
11 Global Neurodegenerative Diseases Competitive Analysis
-
11.1 Boehringer Ingelheim
-
11.1.1 Boehringer Ingelheim Company Details
-
11.1.2 Boehringer Ingelheim Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Boehringer Ingelheim Neurodegenerative Diseases Main Business and Markets Served
-
11.1.4 Boehringer Ingelheim Neurodegenerative Diseases Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Chongqing Zein Pharmaceutical
-
11.2.1 Chongqing Zein Pharmaceutical Company Details
-
11.2.2 Chongqing Zein Pharmaceutical Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Chongqing Zein Pharmaceutical Neurodegenerative Diseases Main Business and Markets Served
-
11.2.4 Chongqing Zein Pharmaceutical Neurodegenerative Diseases Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Eisai
-
11.3.1 Eisai Company Details
-
11.3.2 Eisai Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Eisai Neurodegenerative Diseases Main Business and Markets Served
-
11.3.4 Eisai Neurodegenerative Diseases Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Novartis
-
11.4.1 Novartis Company Details
-
11.4.2 Novartis Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Novartis Neurodegenerative Diseases Main Business and Markets Served
-
11.4.4 Novartis Neurodegenerative Diseases Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Bayer Schering Pharma AG
-
11.5.1 Bayer Schering Pharma AG Company Details
-
11.5.2 Bayer Schering Pharma AG Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Bayer Schering Pharma AG Neurodegenerative Diseases Main Business and Markets Served
-
11.5.4 Bayer Schering Pharma AG Neurodegenerative Diseases Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Addex Pharmaceutical
-
11.6.1 Addex Pharmaceutical Company Details
-
11.6.2 Addex Pharmaceutical Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Addex Pharmaceutical Neurodegenerative Diseases Main Business and Markets Served
-
11.6.4 Addex Pharmaceutical Neurodegenerative Diseases Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Yangtze River Pharmaceutical Group
-
11.7.1 Yangtze River Pharmaceutical Group Company Details
-
11.7.2 Yangtze River Pharmaceutical Group Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Yangtze River Pharmaceutical Group Neurodegenerative Diseases Main Business and Markets Served
-
11.7.4 Yangtze River Pharmaceutical Group Neurodegenerative Diseases Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 AstraZeneca
-
11.8.1 AstraZeneca Company Details
-
11.8.2 AstraZeneca Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 AstraZeneca Neurodegenerative Diseases Main Business and Markets Served
-
11.8.4 AstraZeneca Neurodegenerative Diseases Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Yumanity Therapeutics
-
11.9.1 Yumanity Therapeutics Company Details
-
11.9.2 Yumanity Therapeutics Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Yumanity Therapeutics Neurodegenerative Diseases Main Business and Markets Served
-
11.9.4 Yumanity Therapeutics Neurodegenerative Diseases Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 HLundbeck A/S
-
11.10.1 HLundbeck A/S Company Details
-
11.10.2 HLundbeck A/S Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 HLundbeck A/S Neurodegenerative Diseases Main Business and Markets Served
-
11.10.4 HLundbeck A/S Neurodegenerative Diseases Product Portfolio
-
11.10.5 Recent Research and Development Strategies
-
11.11 Jiangsu Hansoh Pharmaceutical
-
11.11.1 Jiangsu Hansoh Pharmaceutical Company Details
-
11.11.2 Jiangsu Hansoh Pharmaceutical Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
11.11.3 Jiangsu Hansoh Pharmaceutical Neurodegenerative Diseases Main Business and Markets Served
-
11.11.4 Jiangsu Hansoh Pharmaceutical Neurodegenerative Diseases Product Portfolio
-
11.11.5 Recent Research and Development Strategies
-
11.12 Biogen Idec
-
11.12.1 Biogen Idec Company Details
-
11.12.2 Biogen Idec Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
11.12.3 Biogen Idec Neurodegenerative Diseases Main Business and Markets Served
-
11.12.4 Biogen Idec Neurodegenerative Diseases Product Portfolio
-
11.12.5 Recent Research and Development Strategies
-
11.13 Merck Serono
-
11.13.1 Merck Serono Company Details
-
11.13.2 Merck Serono Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
11.13.3 Merck Serono Neurodegenerative Diseases Main Business and Markets Served
-
11.13.4 Merck Serono Neurodegenerative Diseases Product Portfolio
-
11.13.5 Recent Research and Development Strategies
-
11.14 Bial
-
11.14.1 Bial Company Details
-
11.14.2 Bial Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
11.14.3 Bial Neurodegenerative Diseases Main Business and Markets Served
-
11.14.4 Bial Neurodegenerative Diseases Product Portfolio
-
11.14.5 Recent Research and Development Strategies
-
11.15 Asubio Pharmaceutical
-
11.15.1 Asubio Pharmaceutical Company Details
-
11.15.2 Asubio Pharmaceutical Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
11.15.3 Asubio Pharmaceutical Neurodegenerative Diseases Main Business and Markets Served
-
11.15.4 Asubio Pharmaceutical Neurodegenerative Diseases Product Portfolio
-
11.15.5 Recent Research and Development Strategies
-
11.16 Amarin
-
11.16.1 Amarin Company Details
-
11.16.2 Amarin Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
11.16.3 Amarin Neurodegenerative Diseases Main Business and Markets Served
-
11.16.4 Amarin Neurodegenerative Diseases Product Portfolio
-
11.16.5 Recent Research and Development Strategies
-
11.17 Alector
-
11.17.1 Alector Company Details
-
11.17.2 Alector Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
11.17.3 Alector Neurodegenerative Diseases Main Business and Markets Served
-
11.17.4 Alector Neurodegenerative Diseases Product Portfolio
-
11.17.5 Recent Research and Development Strategies
-
11.18 UCB
-
11.18.1 UCB Company Details
-
11.18.2 UCB Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
11.18.3 UCB Neurodegenerative Diseases Main Business and Markets Served
-
11.18.4 UCB Neurodegenerative Diseases Product Portfolio
-
11.18.5 Recent Research and Development Strategies
-
11.19 Pfizer
-
11.19.1 Pfizer Company Details
-
11.19.2 Pfizer Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
11.19.3 Pfizer Neurodegenerative Diseases Main Business and Markets Served
-
11.19.4 Pfizer Neurodegenerative Diseases Product Portfolio
-
11.19.5 Recent Research and Development Strategies
-
11.20 Teva Pharmaceutical
-
11.20.1 Teva Pharmaceutical Company Details
-
11.20.2 Teva Pharmaceutical Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
11.20.3 Teva Pharmaceutical Neurodegenerative Diseases Main Business and Markets Served
-
11.20.4 Teva Pharmaceutical Neurodegenerative Diseases Product Portfolio
-
11.20.5 Recent Research and Development Strategies
12 Global Neurodegenerative Diseases Market Outlook by Types and Applications to 2028
-
12.1 Global Neurodegenerative Diseases Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global NMDA Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global SSRIs Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Dopamine Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Neurodegenerative Diseases Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Parkinson’s disease Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Huntington disease Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Amyotrophic Lateral Sclerosis Consumption Forecast and Growth Rate (2022-2028)
-
12.2.4 Global Alzheimer’s disease Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Neurodegenerative Diseases Market Analysis and Outlook to 2028
-
13.1 Global Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.2.2 Canada Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.2.3 Mexico Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.3.2 UK Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.3.3 Spain Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.3.4 Belgium Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.3.5 France Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.3.6 Italy Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.3.7 Denmark Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.3.8 Finland Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.3.9 Norway Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.3.10 Sweden Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.3.11 Poland Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.3.12 Russia Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.3.13 Turkey Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.4.2 Japan Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.4.3 India Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.4.4 South Korea Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.4.8 Thailand Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.4.9 Singapore Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.4.11 Philippines Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.5.2 Colombia Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.5.3 Chile Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.5.4 Argentina Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.5.6 Peru Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.6.3 Oman Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.6.4 Qatar Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.7.2 South Africa Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.7.3 Egypt Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.7.4 Algeria Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Neurodegenerative Diseases Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Neurodegenerative Diseases Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Neurodegenerative Diseases
-
Figure of Neurodegenerative Diseases Picture
-
Table Global Neurodegenerative Diseases Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Neurodegenerative Diseases Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global NMDA Consumption and Growth Rate (2017-2022)
-
Figure Global SSRIs Consumption and Growth Rate (2017-2022)
-
Figure Global Dopamine Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global Parkinson’s disease Consumption and Growth Rate (2017-2022)
-
Figure Global Huntington disease Consumption and Growth Rate (2017-2022)
-
Figure Global Amyotrophic Lateral Sclerosis Consumption and Growth Rate (2017-2022)
-
Figure Global Alzheimer’s disease Consumption and Growth Rate (2017-2022)
-
Figure Global Neurodegenerative Diseases Consumption by Country (2017-2022)
-
Table North America Neurodegenerative Diseases Consumption by Country (2017-2022)
-
Figure United States Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Canada Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Mexico Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Table Europe Neurodegenerative Diseases Consumption by Country (2017-2022)
-
Figure Germany Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure UK Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Spain Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Belgium Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure France Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Italy Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Denmark Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Finland Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Norway Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Sweden Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Poland Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Russia Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Turkey Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Table APAC Neurodegenerative Diseases Consumption by Country (2017-2022)
-
Figure China Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Japan Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure India Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure South Korea Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Thailand Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Singapore Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Philippines Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Table South America Neurodegenerative Diseases Consumption by Country (2017-2022)
-
Figure Brazil Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Colombia Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Chile Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Argentina Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Peru Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Table GCC Neurodegenerative Diseases Consumption by Country (2017-2022)
-
Figure Bahrain Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Oman Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Qatar Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Table Africa Neurodegenerative Diseases Consumption by Country (2017-2022)
-
Figure Nigeria Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure South Africa Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Egypt Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure Algeria Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Table Oceania Neurodegenerative Diseases Consumption by Country (2017-2022)
-
Figure Australia Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Neurodegenerative Diseases Consumption and Growth Rate (2017-2022)
-
Table Boehringer Ingelheim Company Details
-
Table Boehringer Ingelheim Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
Table Boehringer Ingelheim Neurodegenerative Diseases Main Business and Markets Served
-
Table Boehringer Ingelheim Neurodegenerative Diseases Product Portfolio
-
Table Chongqing Zein Pharmaceutical Company Details
-
Table Chongqing Zein Pharmaceutical Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
Table Chongqing Zein Pharmaceutical Neurodegenerative Diseases Main Business and Markets Served
-
Table Chongqing Zein Pharmaceutical Neurodegenerative Diseases Product Portfolio
-
Table Eisai Company Details
-
Table Eisai Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eisai Neurodegenerative Diseases Main Business and Markets Served
-
Table Eisai Neurodegenerative Diseases Product Portfolio
-
Table Novartis Company Details
-
Table Novartis Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis Neurodegenerative Diseases Main Business and Markets Served
-
Table Novartis Neurodegenerative Diseases Product Portfolio
-
Table Bayer Schering Pharma AG Company Details
-
Table Bayer Schering Pharma AG Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bayer Schering Pharma AG Neurodegenerative Diseases Main Business and Markets Served
-
Table Bayer Schering Pharma AG Neurodegenerative Diseases Product Portfolio
-
Table Addex Pharmaceutical Company Details
-
Table Addex Pharmaceutical Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
Table Addex Pharmaceutical Neurodegenerative Diseases Main Business and Markets Served
-
Table Addex Pharmaceutical Neurodegenerative Diseases Product Portfolio
-
Table Yangtze River Pharmaceutical Group Company Details
-
Table Yangtze River Pharmaceutical Group Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
Table Yangtze River Pharmaceutical Group Neurodegenerative Diseases Main Business and Markets Served
-
Table Yangtze River Pharmaceutical Group Neurodegenerative Diseases Product Portfolio
-
Table AstraZeneca Company Details
-
Table AstraZeneca Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
Table AstraZeneca Neurodegenerative Diseases Main Business and Markets Served
-
Table AstraZeneca Neurodegenerative Diseases Product Portfolio
-
Table Yumanity Therapeutics Company Details
-
Table Yumanity Therapeutics Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
Table Yumanity Therapeutics Neurodegenerative Diseases Main Business and Markets Served
-
Table Yumanity Therapeutics Neurodegenerative Diseases Product Portfolio
-
Table HLundbeck A/S Company Details
-
Table HLundbeck A/S Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
Table HLundbeck A/S Neurodegenerative Diseases Main Business and Markets Served
-
Table HLundbeck A/S Neurodegenerative Diseases Product Portfolio
-
Table Jiangsu Hansoh Pharmaceutical Company Details
-
Table Jiangsu Hansoh Pharmaceutical Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
Table Jiangsu Hansoh Pharmaceutical Neurodegenerative Diseases Main Business and Markets Served
-
Table Jiangsu Hansoh Pharmaceutical Neurodegenerative Diseases Product Portfolio
-
Table Biogen Idec Company Details
-
Table Biogen Idec Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
Table Biogen Idec Neurodegenerative Diseases Main Business and Markets Served
-
Table Biogen Idec Neurodegenerative Diseases Product Portfolio
-
Table Merck Serono Company Details
-
Table Merck Serono Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck Serono Neurodegenerative Diseases Main Business and Markets Served
-
Table Merck Serono Neurodegenerative Diseases Product Portfolio
-
Table Bial Company Details
-
Table Bial Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bial Neurodegenerative Diseases Main Business and Markets Served
-
Table Bial Neurodegenerative Diseases Product Portfolio
-
Table Asubio Pharmaceutical Company Details
-
Table Asubio Pharmaceutical Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
Table Asubio Pharmaceutical Neurodegenerative Diseases Main Business and Markets Served
-
Table Asubio Pharmaceutical Neurodegenerative Diseases Product Portfolio
-
Table Amarin Company Details
-
Table Amarin Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
Table Amarin Neurodegenerative Diseases Main Business and Markets Served
-
Table Amarin Neurodegenerative Diseases Product Portfolio
-
Table Alector Company Details
-
Table Alector Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
Table Alector Neurodegenerative Diseases Main Business and Markets Served
-
Table Alector Neurodegenerative Diseases Product Portfolio
-
Table UCB Company Details
-
Table UCB Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
Table UCB Neurodegenerative Diseases Main Business and Markets Served
-
Table UCB Neurodegenerative Diseases Product Portfolio
-
Table Pfizer Company Details
-
Table Pfizer Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Neurodegenerative Diseases Main Business and Markets Served
-
Table Pfizer Neurodegenerative Diseases Product Portfolio
-
Table Teva Pharmaceutical Company Details
-
Table Teva Pharmaceutical Neurodegenerative Diseases Sales, Price, Value and Gross Profit (2017-2022)
-
Table Teva Pharmaceutical Neurodegenerative Diseases Main Business and Markets Served
-
Table Teva Pharmaceutical Neurodegenerative Diseases Product Portfolio
-
Figure Global NMDA Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global SSRIs Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Dopamine Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Parkinson’s disease Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Huntington disease Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Amyotrophic Lateral Sclerosis Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Alzheimer’s disease Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Neurodegenerative Diseases Consumption Forecast by Country (2022-2028)
-
Table North America Neurodegenerative Diseases Consumption Forecast by Country (2022-2028)
-
Figure United States Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Neurodegenerative Diseases Consumption Forecast by Country (2022-2028)
-
Figure Germany Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Neurodegenerative Diseases Consumption Forecast by Country (2022-2028)
-
Figure China Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Neurodegenerative Diseases Consumption Forecast by Country (2022-2028)
-
Figure Brazil Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Neurodegenerative Diseases Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Neurodegenerative Diseases Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Neurodegenerative Diseases Consumption Forecast by Country (2022-2028)
-
Figure Australia Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Neurodegenerative Diseases Consumption Forecast and Growth Rate (2022-2028)
-
